Home » AIFA warns to avoid some cold medicines

AIFA warns to avoid some cold medicines

by admin
AIFA warns to avoid some cold medicines

AIFA issues warning about the potential risks of drugs containing pseudoephedrine

In a recent statement, the Italian Medicines Agency (AIFA) has raised concerns about the potential risks associated with drugs commonly prescribed for cold and nasal congestion. The active ingredient in question is pseudoephedrine, found in numerous over-the-counter medicines.

The AIFA note, drawn up in collaboration with European regulatory authorities, highlighted a series of risks associated with the use of medicines containing pseudoephedrine. These risks include posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS), which have been found in patients who have used these cold medications.

The statement also pointed out specific categories of patients who should avoid using drugs containing pseudoephedrine, including those with severe or uncontrolled hypertension, as well as those with acute or chronic kidney disease. It is crucial that patients, especially those with pre-existing conditions, are informed about the potential risks associated with the use of these cold medicines and consult a doctor before starting any treatment.

Patients should also be aware of warning signs such as sudden, intense headaches, nausea, vomiting, mental confusion, and visual disturbances, which may indicate the presence of serious conditions that require immediate medical attention.

The AIFA note emphasizes the importance of stopping the use of drugs containing pseudoephedrine at the first suspicion of related symptoms and seeking medical attention to assess the extent of damage and undertake appropriate treatment.

Despite the alarming discovery, there is reason to hope as all reported cases of PRES and RCVS resolved positively with simple discontinuation of the drug and appropriate treatment of symptoms. No deaths have been documented, offering a glimmer of hope amid the worries.

See also  Minister Schillaci, commitment to greater personal health safety

It is essential that health authorities and regulators continue to closely monitor the use of pseudoephedrine in over-the-counter medicines and take appropriate action to protect public health. Only through a collaborative and coordinated effort will it be possible to effectively mitigate the risks associated with this compound and ensure the safe and responsible use of medicines.

You may also like

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy